Evidence map›Paper›PMID 37463569›Full record

ArticlePathobiology : journal of immunopathology, molecular and cellular biology2023

Critical Evaluation of Transcripts and Long Noncoding RNA Expression Levels in Prostate Cancer Following Radical Prostatectomy.

Christian Ruiz, Ilaria Alborelli, Massimilinao Manzo, Byron Calgua, Eveline Barbara Keller, Vincent Vuaroqueaux, Luca Quagliata, Cyrill A Rentsch, Giulio Cesare Spagnoli, Pierre André Diener and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathobiology : journal of immunopathology, molecular and cellular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Role of NOncology reports · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Christian RuizInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Ilaria AlborelliInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Massimilinao ManzoInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Byron CalguaInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Eveline Barbara KellerInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Vincent Vuaroqueaux4HF Biotec, Freiburg, Germany.
Luca QuagliataInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Cyrill A RentschDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
Giulio Cesare SpagnoliNational Research Council, Institute of Translational Pharmacology, Rome, Italy.
Pierre André DienerPathology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Lukas BubendorfInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Rudolf MorantTumor-und Brustzentrum ZeTuP, St. Gallen, Switzerland.
former members of the Urology Team in St. Gallen
Serenella Eppenberger-CastoriInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
University of Basel · CHIstituto di Farmacologia Traslazionale · ITKantonsspital St. Gallen · CHProtestant University of Applied Sciences Freiburg · DETumor- und Brustzentrum ZeTuP Silberturm · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe clinical course of prostate cancer (PCa) is highly variable, ranging from indolent behavior to rapid metastatic progression. The Gleason score is widely accepted as the primary histologic assessment tool with significant prognostic value. However, additional biomarkers are required to better stratify patients, particularly those at intermediate risk.

methodsIn this study, we analyzed the expression of 86 cancer hallmark genes in 171 patients with PCa who underwent radical prostatectomy and focused on the outcome of the 137 patients with postoperative R0-PSA0 status.

resultsLow expression of the IGF1 and SRD52A, and high expression of TIMP2, PLAUR, S100A2, and CANX genes were associated with biochemical recurrence (BR), defined as an increase of prostate-specific antigen above 0.2 ng/mL. Furthermore, the analysis of the expression of 462 noncoding RNAs (ncRNA) in a sub-cohort of 39 patients with Gleason score 7 tumors revealed that high levels of expression of the ncRNAs LINC00624, LINC00593, LINC00482, and cd27-AS1 were significantly associated with BR. Our findings provide further evidence for tumor-promoting roles of ncRNAs in PCa patients at intermediate risk. The strong correlation between expression of LINC00624 and KRT8 gene, encoding a well-known cell surface protein present in PCa, further supports a potential contribution of this ncRNA to PCa progression.

conclusionWhile larger and further studies are needed to define the role of these genes/ncRNA in PCa, our findings pave the way toward the identification of a subgroup of patients at intermediate risk who may benefit from adjuvant treatments and new therapeutic agents.

Indexed as

Prostatic NeoplasmsRNA, Long NoncodingHumansMaleNeoplasm GradingNeoplasm Recurrence, LocalProstateProstatectomyProstate-Specific AntigenProstate-Specific AntigenRNA, Long NoncodingBiochemical recurrenceBiochemical recurrence-free survivalGleason scoreLong noncoding RNAProstate cancer

Identifiers

PMID37463569
PMCPMC10733933
OpenAlexW4384664804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.